Trial Profile
A phase III trial of Acelarin (NUC-1031) in patients with biliary cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2015
Price :
$35
*
At a glance
- Drugs Fosgemcitabine palabenamide (Primary)
- Indications Biliary cancer
- Focus Registrational; Therapeutic Use
- 03 Jul 2015 New trial record